Neoadjuvant Chemotherapy with Cisplatin and Methotrexate in Patients with Muscle-Invasive Bladder Tumours

Authors

  • Lisa Sengeløv From the Departments of Oncology (L. Sengelv) and Urology (K. Steven), University Hospital Herlev, Herlev, Copenhagen, Department of Oncology, Aarhus University Hospital, Aarhus (H. von der Maase, O.S. Nielsen), Department of Urology, Skejby University Hospital, Aarhus (F. Lundbech), Departments of Pathology (H. Barlebo), Urology (T. Krarup) and Oncology (D. Pedersen), A lborg Hospital, AE lborg, Department of Urology Gentofte University Hospital (H. Colstrup), Department of Oncology, The Finsen Centre, Rigshospitalet, Copenhagen (S.A. Engelholm), Departments of Oncology (E. LindegaE rd Madsen) and Urology (S. Mommsen), Odense University Hospital, Odense, Department of Urology,Hillerod Hospital, Hillerod (Hans Henrik Meyhoff) and the Department of Urology, Rigshospitalet, Copenhagen (B. Srensen), Denmark
  • Hans Von Der Maase From the Departments of Oncology (L. Sengelv) and Urology (K. Steven), University Hospital Herlev, Herlev, Copenhagen, Department of Oncology, Aarhus University Hospital, Aarhus (H. von der Maase, O.S. Nielsen), Department of Urology, Skejby University Hospital, Aarhus (F. Lundbech), Departments of Pathology (H. Barlebo), Urology (T. Krarup) and Oncology (D. Pedersen), A lborg Hospital, AE lborg, Department of Urology Gentofte University Hospital (H. Colstrup), Department of Oncology, The Finsen Centre, Rigshospitalet, Copenhagen (S.A. Engelholm), Departments of Oncology (E. LindegaE rd Madsen) and Urology (S. Mommsen), Odense University Hospital, Odense, Department of Urology,Hillerod Hospital, Hillerod (Hans Henrik Meyhoff) and the Department of Urology, Rigshospitalet, Copenhagen (B. Srensen), Denmark
  • Finn Lundbeck From the Departments of Oncology (L. Sengelv) and Urology (K. Steven), University Hospital Herlev, Herlev, Copenhagen, Department of Oncology, Aarhus University Hospital, Aarhus (H. von der Maase, O.S. Nielsen), Department of Urology, Skejby University Hospital, Aarhus (F. Lundbech), Departments of Pathology (H. Barlebo), Urology (T. Krarup) and Oncology (D. Pedersen), A lborg Hospital, AE lborg, Department of Urology Gentofte University Hospital (H. Colstrup), Department of Oncology, The Finsen Centre, Rigshospitalet, Copenhagen (S.A. Engelholm), Departments of Oncology (E. LindegaE rd Madsen) and Urology (S. Mommsen), Odense University Hospital, Odense, Department of Urology,Hillerod Hospital, Hillerod (Hans Henrik Meyhoff) and the Department of Urology, Rigshospitalet, Copenhagen (B. Srensen), Denmark
  • Henrik Barlebo From the Departments of Oncology (L. Sengelv) and Urology (K. Steven), University Hospital Herlev, Herlev, Copenhagen, Department of Oncology, Aarhus University Hospital, Aarhus (H. von der Maase, O.S. Nielsen), Department of Urology, Skejby University Hospital, Aarhus (F. Lundbech), Departments of Pathology (H. Barlebo), Urology (T. Krarup) and Oncology (D. Pedersen), A lborg Hospital, AE lborg, Department of Urology Gentofte University Hospital (H. Colstrup), Department of Oncology, The Finsen Centre, Rigshospitalet, Copenhagen (S.A. Engelholm), Departments of Oncology (E. LindegaE rd Madsen) and Urology (S. Mommsen), Odense University Hospital, Odense, Department of Urology,Hillerod Hospital, Hillerod (Hans Henrik Meyhoff) and the Department of Urology, Rigshospitalet, Copenhagen (B. Srensen), Denmark
  • Hans Colstrup From the Departments of Oncology (L. Sengelv) and Urology (K. Steven), University Hospital Herlev, Herlev, Copenhagen, Department of Oncology, Aarhus University Hospital, Aarhus (H. von der Maase, O.S. Nielsen), Department of Urology, Skejby University Hospital, Aarhus (F. Lundbech), Departments of Pathology (H. Barlebo), Urology (T. Krarup) and Oncology (D. Pedersen), A lborg Hospital, AE lborg, Department of Urology Gentofte University Hospital (H. Colstrup), Department of Oncology, The Finsen Centre, Rigshospitalet, Copenhagen (S.A. Engelholm), Departments of Oncology (E. LindegaE rd Madsen) and Urology (S. Mommsen), Odense University Hospital, Odense, Department of Urology,Hillerod Hospital, Hillerod (Hans Henrik Meyhoff) and the Department of Urology, Rigshospitalet, Copenhagen (B. Srensen), Denmark
  • Svend Aage Engelholm From the Departments of Oncology (L. Sengelv) and Urology (K. Steven), University Hospital Herlev, Herlev, Copenhagen, Department of Oncology, Aarhus University Hospital, Aarhus (H. von der Maase, O.S. Nielsen), Department of Urology, Skejby University Hospital, Aarhus (F. Lundbech), Departments of Pathology (H. Barlebo), Urology (T. Krarup) and Oncology (D. Pedersen), A lborg Hospital, AE lborg, Department of Urology Gentofte University Hospital (H. Colstrup), Department of Oncology, The Finsen Centre, Rigshospitalet, Copenhagen (S.A. Engelholm), Departments of Oncology (E. LindegaE rd Madsen) and Urology (S. Mommsen), Odense University Hospital, Odense, Department of Urology,Hillerod Hospital, Hillerod (Hans Henrik Meyhoff) and the Department of Urology, Rigshospitalet, Copenhagen (B. Srensen), Denmark
  • Torben Krarup From the Departments of Oncology (L. Sengelv) and Urology (K. Steven), University Hospital Herlev, Herlev, Copenhagen, Department of Oncology, Aarhus University Hospital, Aarhus (H. von der Maase, O.S. Nielsen), Department of Urology, Skejby University Hospital, Aarhus (F. Lundbech), Departments of Pathology (H. Barlebo), Urology (T. Krarup) and Oncology (D. Pedersen), A lborg Hospital, AE lborg, Department of Urology Gentofte University Hospital (H. Colstrup), Department of Oncology, The Finsen Centre, Rigshospitalet, Copenhagen (S.A. Engelholm), Departments of Oncology (E. LindegaE rd Madsen) and Urology (S. Mommsen), Odense University Hospital, Odense, Department of Urology,Hillerod Hospital, Hillerod (Hans Henrik Meyhoff) and the Department of Urology, Rigshospitalet, Copenhagen (B. Srensen), Denmark
  • Ebbe Lindegård Madsen From the Departments of Oncology (L. Sengelv) and Urology (K. Steven), University Hospital Herlev, Herlev, Copenhagen, Department of Oncology, Aarhus University Hospital, Aarhus (H. von der Maase, O.S. Nielsen), Department of Urology, Skejby University Hospital, Aarhus (F. Lundbech), Departments of Pathology (H. Barlebo), Urology (T. Krarup) and Oncology (D. Pedersen), A lborg Hospital, AE lborg, Department of Urology Gentofte University Hospital (H. Colstrup), Department of Oncology, The Finsen Centre, Rigshospitalet, Copenhagen (S.A. Engelholm), Departments of Oncology (E. LindegaE rd Madsen) and Urology (S. Mommsen), Odense University Hospital, Odense, Department of Urology,Hillerod Hospital, Hillerod (Hans Henrik Meyhoff) and the Department of Urology, Rigshospitalet, Copenhagen (B. Srensen), Denmark
  • Hans Henrik Meyhoff From the Departments of Oncology (L. Sengelv) and Urology (K. Steven), University Hospital Herlev, Herlev, Copenhagen, Department of Oncology, Aarhus University Hospital, Aarhus (H. von der Maase, O.S. Nielsen), Department of Urology, Skejby University Hospital, Aarhus (F. Lundbech), Departments of Pathology (H. Barlebo), Urology (T. Krarup) and Oncology (D. Pedersen), A lborg Hospital, AE lborg, Department of Urology Gentofte University Hospital (H. Colstrup), Department of Oncology, The Finsen Centre, Rigshospitalet, Copenhagen (S.A. Engelholm), Departments of Oncology (E. LindegaE rd Madsen) and Urology (S. Mommsen), Odense University Hospital, Odense, Department of Urology,Hillerod Hospital, Hillerod (Hans Henrik Meyhoff) and the Department of Urology, Rigshospitalet, Copenhagen (B. Srensen), Denmark
  • Søren Mommsen From the Departments of Oncology (L. Sengelv) and Urology (K. Steven), University Hospital Herlev, Herlev, Copenhagen, Department of Oncology, Aarhus University Hospital, Aarhus (H. von der Maase, O.S. Nielsen), Department of Urology, Skejby University Hospital, Aarhus (F. Lundbech), Departments of Pathology (H. Barlebo), Urology (T. Krarup) and Oncology (D. Pedersen), A lborg Hospital, AE lborg, Department of Urology Gentofte University Hospital (H. Colstrup), Department of Oncology, The Finsen Centre, Rigshospitalet, Copenhagen (S.A. Engelholm), Departments of Oncology (E. LindegaE rd Madsen) and Urology (S. Mommsen), Odense University Hospital, Odense, Department of Urology,Hillerod Hospital, Hillerod (Hans Henrik Meyhoff) and the Department of Urology, Rigshospitalet, Copenhagen (B. Srensen), Denmark
  • Ole Steen Nielsen From the Departments of Oncology (L. Sengelv) and Urology (K. Steven), University Hospital Herlev, Herlev, Copenhagen, Department of Oncology, Aarhus University Hospital, Aarhus (H. von der Maase, O.S. Nielsen), Department of Urology, Skejby University Hospital, Aarhus (F. Lundbech), Departments of Pathology (H. Barlebo), Urology (T. Krarup) and Oncology (D. Pedersen), A lborg Hospital, AE lborg, Department of Urology Gentofte University Hospital (H. Colstrup), Department of Oncology, The Finsen Centre, Rigshospitalet, Copenhagen (S.A. Engelholm), Departments of Oncology (E. LindegaE rd Madsen) and Urology (S. Mommsen), Odense University Hospital, Odense, Department of Urology,Hillerod Hospital, Hillerod (Hans Henrik Meyhoff) and the Department of Urology, Rigshospitalet, Copenhagen (B. Srensen), Denmark
  • Dorte Pedersen From the Departments of Oncology (L. Sengelv) and Urology (K. Steven), University Hospital Herlev, Herlev, Copenhagen, Department of Oncology, Aarhus University Hospital, Aarhus (H. von der Maase, O.S. Nielsen), Department of Urology, Skejby University Hospital, Aarhus (F. Lundbech), Departments of Pathology (H. Barlebo), Urology (T. Krarup) and Oncology (D. Pedersen), A lborg Hospital, AE lborg, Department of Urology Gentofte University Hospital (H. Colstrup), Department of Oncology, The Finsen Centre, Rigshospitalet, Copenhagen (S.A. Engelholm), Departments of Oncology (E. LindegaE rd Madsen) and Urology (S. Mommsen), Odense University Hospital, Odense, Department of Urology,Hillerod Hospital, Hillerod (Hans Henrik Meyhoff) and the Department of Urology, Rigshospitalet, Copenhagen (B. Srensen), Denmark
  • Kenneth Steven From the Departments of Oncology (L. Sengelv) and Urology (K. Steven), University Hospital Herlev, Herlev, Copenhagen, Department of Oncology, Aarhus University Hospital, Aarhus (H. von der Maase, O.S. Nielsen), Department of Urology, Skejby University Hospital, Aarhus (F. Lundbech), Departments of Pathology (H. Barlebo), Urology (T. Krarup) and Oncology (D. Pedersen), A lborg Hospital, AE lborg, Department of Urology Gentofte University Hospital (H. Colstrup), Department of Oncology, The Finsen Centre, Rigshospitalet, Copenhagen (S.A. Engelholm), Departments of Oncology (E. LindegaE rd Madsen) and Urology (S. Mommsen), Odense University Hospital, Odense, Department of Urology,Hillerod Hospital, Hillerod (Hans Henrik Meyhoff) and the Department of Urology, Rigshospitalet, Copenhagen (B. Srensen), Denmark
  • Bent Sørensen From the Departments of Oncology (L. Sengelv) and Urology (K. Steven), University Hospital Herlev, Herlev, Copenhagen, Department of Oncology, Aarhus University Hospital, Aarhus (H. von der Maase, O.S. Nielsen), Department of Urology, Skejby University Hospital, Aarhus (F. Lundbech), Departments of Pathology (H. Barlebo), Urology (T. Krarup) and Oncology (D. Pedersen), A lborg Hospital, AE lborg, Department of Urology Gentofte University Hospital (H. Colstrup), Department of Oncology, The Finsen Centre, Rigshospitalet, Copenhagen (S.A. Engelholm), Departments of Oncology (E. LindegaE rd Madsen) and Urology (S. Mommsen), Odense University Hospital, Odense, Department of Urology,Hillerod Hospital, Hillerod (Hans Henrik Meyhoff) and the Department of Urology, Rigshospitalet, Copenhagen (B. Srensen), Denmark

DOI:

https://doi.org/10.1080/028418602320405041

Abstract

This prospective, randomized study based on two associated trials was designed to evaluate the effect of neoadjuvant chemotherapy with cisplatin and methotrexate with folinic acid rescue or no chemotherapy prior to local treatment in patients with T2-T4b, NX-3, MO transitional cell carcinoma of the bladder. In the first trial, local treatment consisted of cystectomy (DAVECA 8901) and in the other trial the treatment was radiotherapy (DAVECA 8902); 153 eligible patients were randomized. 

Downloads

Download data is not yet available.

Downloads

Published

2023-11-17

How to Cite

Sengeløv, L. ., Der Maase, H. V. ., Lundbeck, F. ., Barlebo, H. ., Colstrup, H., Engelholm, S. A. ., … Sørensen, B. . (2023). Neoadjuvant Chemotherapy with Cisplatin and Methotrexate in Patients with Muscle-Invasive Bladder Tumours. Acta Oncologica, 41(5). https://doi.org/10.1080/028418602320405041

Issue

Vol. 41 No. 5 (2002): Acta Oncologica

Section

Articles